La bourse est fermée

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
291,12-3,94 (-1,34 %)
À la clôture : 04:00PM EDT
291,12 0,00 (0,00 %)
Échanges après Bourse : 04:09PM EDT

Abiomed, Inc.

22 Cherry Hill Drive
Danvers, MA 01923
United States
978 646 1400
https://www.abiomed.com

Secteur(s)Healthcare
Secteur d’activitéMedical Devices
Employés à temps plein2 003

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Michael R. MinogueChairman, CEO & Pres3,04M26,95M1967
Mr. Todd A. TrappExec. VP & CFO914,93kS.O.1971
Mr. Marc A. BeganExec. VP, Gen. Counsel & Sec.818,64kS.O.1967
Mr. Andrew J. GreenfieldExec. VP & Chief Commercial Officer804,95kS.O.1973
Dr. David M. Weber Ph.D.Scientific & Technology Advisor1,02M6,79M1961
Mr. Matthew T. PlanoExec. VP of Global Operations & IntegrationS.O.S.O.1965
Dr. Thorsten Siess Ph.D.VP & CTOS.O.S.O.S.O.
Ms. Ingrid Goldberg WardDirector of Investor RelationsS.O.S.O.S.O.
Sarah KarrCommunications Mang.S.O.S.O.S.O.
Mr. Michael G. HowleyVP & GM of Global SalesS.O.S.O.1964
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Abiomed, Inc. en date du 31 juillet 2022 est 10. Les scores principaux sont Audit : 9; Société : 8; Droits des actionnaires : 10; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.